NeuroOne Medical TechnologiesNMTC -4.04%43 PB Ratio is 5.21 as of Jun. 26, 2026, which is 8% below its 10-year median of 5.66. GuruFocus rates NMTC with a GF Score™ of 43/100 and a GF Value™ of $6.58 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 788 Medical Devices & Instruments companies, NeuroOne Medical Technologies ranks worse than 80.58% on this metric.
The historical rank and industry rank for NeuroOne Medical Technologies's PB Ratio or its related term are showing as below:
NMTC'
s PB Ratio Range Over the Past 10 Years
Min: 0.65 Med: 5.66 Max: 59.89
Current: 5.21
During the past 13 years, NeuroOne Medical Technologies's highest PB Ratio was 59.89. The lowest was 0.65. And the median was 5.66.
NMTC's PB Ratio is ranked worse than 80.58% of 788
companies
in the Medical Devices & Instruments industry
Industry Median: 2.02
vs NMTC: 5.21
During the past 12 months, NeuroOne Medical Technologies's average Book Value Per Share Growth Rate was 190.20% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -37.90% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was -31.60% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of NeuroOne Medical Technologies was -2.20% per year. The lowest was -353.00% per year. And the median was -82.45% per year.
Back to Basics: PB Ratio
NeuroOne Medical Technologies (NAS:NMTC) PB Ratio Explanation
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
NeuroOne Medical Technologies PB Ratio Related Terms
NeuroOne Medical Technologies PB Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, NeuroOne Medical Technologies's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeuroOne Medical Technologies PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, NeuroOne Medical Technologies's PB Ratio distribution charts can be found below:
* The bar in red indicates where NeuroOne Medical Technologies's PB Ratio falls into.
NeuroOne Medical Technologies PB Ratio Calculation
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
NeuroOne Medical Technologies (NMTC) has a PB Ratio of 5.21 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NeuroOne Medical Technologies and its competitors. This is near median its historical median of 5.66. Over the past decade, NeuroOne Medical Technologies' PB Ratio has ranged from 0.65 to 59.89. According to the industry distribution chart, NeuroOne Medical Technologies ranks #635 out of 788 companies in the Medical Devices & Instruments industry, placing it in the top 80.6%.
Is NeuroOne Medical Technologies' PB Ratio too high?
NeuroOne Medical Technologies' current PB Ratio of 5.21 is near median its 10-year median of 5.66. Over the past 10 years, this metric has ranged from a low of 0.65 to a high of 59.89. The Medical Devices & Instruments industry median PB Ratio is 2.02. NeuroOne Medical Technologies' value of 5.21 is 157.9% above this industry median. Based on the distribution chart, NeuroOne Medical Technologies ranks #635 out of 788 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, NeuroOne Medical Technologies has a GF Score™ of 43/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does NeuroOne Medical Technologies' PB Ratio compare to CTSO and CODX?
According to the Medical Devices & Instruments industry distribution chart, NeuroOne Medical Technologies ranks #635 out of 788 companies for PB Ratio. This places NeuroOne Medical Technologies in the lower half of its industry. The industry median PB Ratio is 2.02. NeuroOne Medical Technologies' value of 5.21 is 157.9% above this benchmark. Historically, NeuroOne Medical Technologies' own PB Ratio has ranged from 0.65 to 59.89 over the past decade. While the company's 10-year median is 5.66 vs. the industry median of 2.02, NeuroOne Medical Technologies has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.02, based on 788 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NeuroOne Medical Technologies's current PB Ratio of 5.21 is 157.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on NeuroOne Medical Technologies and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.02 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NeuroOne Medical Technologies's current PB Ratio is 5.21, which is near median its own 10-year median of 5.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeuroOne Medical Technologies stock overvalued right now?
Based on GuruFocus' analysis, NeuroOne Medical Technologies (NMTC) is currently considered Possible Value Trap. The stock's GF Value™ is $6.58, compared to a current price of $3.25 — trading 50.6% below its estimated fair value. The current PB Ratio is 5.21, which is near median its 10-year median of 5.66 and 157.9% above the Medical Devices & Instruments industry median of 2.02. NeuroOne Medical Technologies' overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For NeuroOne Medical Technologies (NMTC), the current PB Ratio is 5.21 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NeuroOne Medical Technologies (NMTC) Overvalued in 2026?
Based on GuruFocus' analysis, NeuroOne Medical Technologies stock appears to be undervalued.
The current stock price of $3.25 is trading 50.6% below its estimated GF Value™ of $6.58.
GuruFocus considers NeuroOne Medical Technologies to be Possible Value Trap.
Key valuation signals for NMTC:
PB Ratio: 5.21 (near median its 10-year median of 5.66)
GF Value™: $6.58 vs. price of $3.25 (50.6% below fair value)
Industry Position: 157.9% above the Medical Devices & Instruments median (#635 of 788)
No single metric tells the full story. See the NMTC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NeuroOne Medical Technologies Business Description
NeuroOne Medical Technologies Corp is focused on diagnostic, ablation, and deep brain stimulation technology for brain-related conditions such as epilepsy and Parkinson's disease; ablation and stimulation for pain management; and drug delivery with diagnostic and stimulation capabilities. It develops thin film electrode technology for various recording and therapeutic applications, crucial for diagnosing neurological disorders such as epilepsy, Parkinson's disease, dystonia, and essential tremors. The company operates in one segment, developing and commercializing products for neuromodulation, cEEG, and sEEG recording, monitoring, ablation, and brain stimulation, with revenue from Evo Cortical, Evo sEEG, and OneRF Ablation System.
43GF Score
Get the complete analysis for NMTC
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NMTC has been successfully added to your 
